JS Link News
News
0
Ticker
127120.KQ
ISIN
KR7127120004
Actualités Eulerpool JS Link
Actualités de l'action JS Link
JS Link est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant JS Link.
Communiqués de presse relatifs à l'action JS Link
JS Link publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.
JS Link News 2026
Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action JS Link (127120.KQ, ISIN : KR7127120004). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez JS Link.
JS Link Action
JS Link DNA Link, Inc. generates revenue through its genomic analysis services and products. The company offers genome biomarkers excavation products via the enhanced genome integration system (EGIS) brand, which includes high-quality data products, genomic analysis interpretation, and molecular diagnostic kit production technologies. Additionally, DNA Link provides personal genome analysis services under the deoxyribonucleic acid personalized services (DNAGPS) brand, targeting individuals seeking personalized genetic insights. The primary customers for EGIS are healthcare providers and research institutions requiring integrated genomic and clinical data solutions, while DNAGPS serves individual consumers interested in personalized health information. The enhanced genome integration system (EGIS) brand focuses on delivering comprehensive genomic analysis and clinical information integration, catering to the needs of medical professionals and research organizations. DNAGPS targets individual users who want detailed personal genome reports. Both product lines leverage DNA Link's expertise in genomic analysis and molecular diagnostics, ensuring high-quality data and interpretation services. The company's revenue streams are driven by the sale of these branded products to their respective target segments. DNA Link's business model centers around two core product lines: EGIS for professional and institutional clients and DNAGPS for individual consumers. EGIS products are sold to healthcare providers and research institutions that require advanced genomic data analysis and molecular diagnostic solutions. DNAGPS services are marketed directly to consumers seeking personalized genetic information. The company's revenue is derived from the licensing and sale of these branded genomic analysis services and products, with no mention of additional revenue sources in the business description.